MaxCyte, Inc. (NASDAQ:MXCT) Q1 2026 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2026 Earnings Call Transcript May 12, 2026MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.1.
Maxcyte Inc. (MXCT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Cadian Capital Eric Bannasch | 2,201,166 | $2,707,434 | +28% | 0.2% |
| 2. | Renaissance Technologies Jim Simons | 1,910,800 | $2,350,284 | -5% | 0% |
| 3. | AQR Capital Management Cliff Asness | 1,882,776 | $2,315,814 | +55% | 0% |
| 4. | Millennium Management Israel Englander | 1,204,921 | $1,482,053 | +2699% | 0% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,014,778 | $1,248,178 | +926% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.29 | 50,000 | $64,500.00 | 161,811 | 2025-08-13 | Filing | |
| $1.37 | 75,000 | $102,915.00 | 175,000 | 2025-08-13 | Filing | |
| $1.37 | 100,000 | $137,220.00 | 398,328 | 2025-08-13 | Filing | |
| $1.39 | 80,000 | $111,040.00 | 230,577 | 2025-08-13 | Filing | |
| $1.29 | 50,000 | $64,500.00 | 150,879 | 2025-08-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.82 | 10,142 | $8,265.73 | 151,669 | 2026-03-17 | Filing | |
| $2.09 | 10,684 | $22,377.64 | 39,893 | 2025-06-25 | Filing | |
| $3.18 | 1,211 | $3,850.13 | 59,439 | 2025-03-18 | Filing | |
| $3.18 | 353 | $1,122.29 | 64,219 | 2025-03-18 | Filing | |
| $3.18 | 6,939 | $22,061.16 | 111,811 | 2025-03-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 25,833 | $28,933 | 0% | |
| 2. | 5,702 | $6,386 | 0% | |
| 3. | 185 | $207 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Here's Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund" Q1 2026 Investor Letter. A copy of the letter can be downloaded here.
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript March 24, 2026MaxCyte, Inc. misses on earnings expectations. Reported EPS is $-0.09016 EPS, expectations were $-0.06505.
MaxCyte (MXCT) Launches ExPERT DTx Platform to Accelerate High-Throughput Drug Discovery
MaxCyte Inc. (NASDAQ:MXCT) is one of the best penny stocks under $1 to buy right now.
13 Best Penny Stocks Under $1 to Buy Right Now
Earlier on January 8, Royce Investment Partners co-chief investment officer Francis Gannon appeared on Yahoo Finance's 'Market Domination Overtime' to suggest that it is time for investors to get on board...
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2025 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) Q3 2025 Earnings Call Transcript November 12, 2025MaxCyte, Inc. misses on earnings expectations. Reported EPS is $-0.1308 EPS, expectations were $-0.11.
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc.
10 Best 52-Week Low Penny Stocks to Buy Now
In this article, we will look at the 10 Best 52-Week Low Penny Stocks to Buy Now. On March 26, Gabelli released its Small Cap Outlook for 2025 and beyond.
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good day, and thank you for standing by. Welcome to the MaxCyte Second Quarter Earnings Conference Call.
MaxCyte, Inc. (MXCT): A Bull Case Theory
We came across a bullish thesis on MaxCyte, Inc. (MXCT) on Substack by OppCost. In this article, we will summarize the bulls’ thesis on MXCT. MaxCyte, Inc.
Hedge Fund Resource Center